The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1.

MLA

Oze, T., et al. “The Real Impact of Telaprevir Dosage on the Antiviral and Side Effects of Telaprevir, Pegylated Interferon and Ribavirin Therapy for Chronic Hepatitis C Patients with HCV Genotype 1.” Journal of Viral Hepatitis, vol. 22, no. 3, Mar. 2015, pp. 254–62. EBSCOhost, https://doi.org/10.1111/jvh.12289.

APA

Oze, T., Hiramatsu, N., Yakushijin, T., Yamada, R., Harada, N., Morishita, N., Oshita, M., Mita, E., Ito, T., Inui, Y., Inada, M., Tamura, S., Yoshihara, H., Imai, Y., Kato, M., Miyagi, T., Yoshida, Y., Tatsumi, T., Kasahara, A., & Hayashi, N. (2015). The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1. Journal of Viral Hepatitis, 22(3), 254–262. https://doi.org/10.1111/jvh.12289

Chicago

Oze, T., N. Hiramatsu, T. Yakushijin, R. Yamada, N. Harada, N. Morishita, M. Oshita, et al. 2015. “The Real Impact of Telaprevir Dosage on the Antiviral and Side Effects of Telaprevir, Pegylated Interferon and Ribavirin Therapy for Chronic Hepatitis C Patients with HCV Genotype 1.” Journal of Viral Hepatitis 22 (3): 254–62. doi:10.1111/jvh.12289.